The H2 blocker ranitidine (Zantac) has been withdrawn from the U.S. market because of concerns over levels of the contaminant N-nitrosodimethylamine, which can increase with time and temperature, posing a risk of cancer. Patients should be told to discard all products containing ranitidine.